"id","label","description","rationale","name","uuid:ID","instanceType"
"StudyDesign_1","","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","dc11c7eb-7e1a-470b-a7c3-08222b859634","StudyDesign"
